Saturday, July 5, 2025 7/5/2025

Plasmonic nanoparticle-mediated immunotherapy to treat metastatic cancer

Award Number: R01EB028078
ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2019
PERIOD OF PERFORMANCE END DATE: 01/31/2025

Group Awards By:

View Award Description

Plasmonic nanoparticle-mediated immunotherapy to treat metastatic cancer - Bladder cancer (BC) is the 4th most common cancer in men and the 11th most common in women. BC has the highest lifetime per-patient treatment cost of all cancers, mainly because of its high recurrence rate. Also, regular invasive cystoscopy and the subsequent surgical treatment of recurrences impair patient quality of life and cause significant morbidity. Therefore, there is a clear clinical need for novel technologies to effectively treat BC, ultimately reducing tumor recurrences, treatment costs, number of radical cystectomies, and mortality. A promising therapeutic platform for cancer is offered by gold nanoparticles (GNP). Taking advantage of gold’s high biocompatibility, GNP can be injected intravenously and accumulate preferentially in cancer cells due to the enhanced permeability and retention effect. Among GNP platforms, gold nanostars (GNS) have great therapeutic potential due to the unique star-shaped geometry that dramatically enhances light absorption and effective conversion into heat due to the plasmonic effect. This photothermal process can be exploited to specifically ablate tumors and, importantly, to amplify the anti-tumor immune response following the highly immunogenic thermal death of cancer cells. Relatedly, many cancers exploit immune checkpoints – such as the interaction between programmed cell death 1 (PD-1) and its ligand (PD-L1) – to evade the anti- cancer immune response. Recent immunotherapies disabling this immune resistance mechanism have shown encouraging clinical results, are FDA approved in BC, but do not offer a permanent cure for most patients. We thus propose to develop the GNS technology for use in SYnergistic iMmuno PHOtothermal NanotherapY (SYMPHONY), a novel therapy that integrates nanotechnology, biophotonics, and immunotherapy. The central hypothesis of this proposal is that combining GNS-mediated photothermal nanotherapy with PD-1/PD-L1 immune checkpoint blockade will result in dramatic therapeutic synergism to treat cancer metastasis. The rationale for this hypothesis is that photothermal therapy not only reduces tumor burden by direct heat-based ablation, but also causes intense immune responses that can be amplified with PD-1/PD-L1 immune checkpoint blockade. The specific aims are: (1) Fabricate and modulate optical properties of next-generation plasmonics GNS to maximize photothermal therapy of deep tumors;; (2) Coat and functionalize GNS to safely improve in vivo BC targeting;; and (3) Evaluate effectiveness of SYMPHONY therapy for treating BC in murine models. The results of our research proposal intends to prove that nanoparticle therapy and immunotherapy can be synergistically combined to produce an antitumor systemic response far superior to either single therapy alone. We will also prove that SYMPHONY triggers an extremely potent systemic response that cures both primary and distant lesions, producing a ‘vaccine’ effect to prevent future BC recurrences. The proposed work will set the stage for SYMPHONY’s rapid future clinical translation to improve life quality and reduce mortality of BC patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2022	DUKE UNIVERSITY	2200 W MAIN ST	DURHAM	NC	27705	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	4	4/29/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	DUKE UNIVERSITY	2200 W MAIN ST	DURHAM	NC	27705	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	4	2/7/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $528,416 )
2022	2022	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	4	1/19/2022	NON-COMPETING CONTINUATION	$475,576
2022	2022	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	4	6/27/2022	NON-COMPETING CONTINUATION	$52,840
														Subtotal = $528,416

Issue Date FY: 2021 ( Subtotal = $524,053 )
2021	2021	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	3	1/6/2021	NON-COMPETING CONTINUATION	$481,274
2021	2021	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	002	3	5/28/2021	NON-COMPETING CONTINUATION	$0
2021	2021	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	3	3/30/2021	NON-COMPETING CONTINUATION	$42,779
														Subtotal = $524,053

Issue Date FY: 2020 ( Subtotal = $532,240 )
2020	2020	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	2	1/22/2020	NON-COMPETING CONTINUATION	$532,240
														Subtotal = $532,240

Issue Date FY: 2019 ( Subtotal = $509,972 )
2019	2019	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	1	4/16/2019	NEW	$509,972
														Subtotal = $509,972

Grand Total All Awards = $2,094,681

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Plasmonic nanoparticle-mediated immunotherapy to treat metastatic cancer

Award Number: R01EB028078

ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2019

PERIOD OF PERFORMANCE END DATE: 01/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer